• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地尔硫䓬多颗粒缓释制剂的研发及体内外评价

Development and in vitro-in vivo evaluation of a multiparticulate sustained release formulation of diltiazem.

作者信息

Li S P, Felt R G, Di Paolo L C, Huang M Y, Williams R O

机构信息

Rhone-Poulenc Rorer Pharmaceuticals Inc., Fort Washington 19034, USA.

出版信息

Pharm Res. 1995 Sep;12(9):1338-42. doi: 10.1023/a:1016229808716.

DOI:10.1023/a:1016229808716
PMID:8570532
Abstract

PURPOSE

To develop and evaluate the in vitro/in vivo performance of diltiazem sustained release pellets that were prepared by the Wurster column process.

METHODS

Pellets containing diltiazem were prepared by spraying a slurry of micronized diltiazem hydrochloride, pharmaceutical glaze and alcohol onto an appropriate mesh fraction of nonpareil seeds using the Wurster column. A two-step drug layering process was used to increase drug loading from 60% to 75%. The oven-dried diltiazem basic pellets were coated with ethylcellulose/dibutyl sebacate coating solution to yield diltiazem sustained release pellets. An open, randomized Latin square, three-way crossover clinical study was used to evaluate the in vivo performance of the coated product.

RESULTS

Altering the mesh fraction of the starting nonpareil seeds for this layering process was found to affect the release characteristics of drug from the pellets. An oven-drying step was required to stabilize the diltiazem basic pellets. The thicker the drug loading layer the longer the oven drying is needed to stabilize the pellets. The diltiazem sustained release pellets produced by these methods displayed sustained release dissolution profiles both in vitro and in vivo. Diltiazem basic pellets coated with a 0.6% ethylcellulose/dibutyl sebacate coating showed a different rate of absorption (lower Cmax and higher Tmax) and the same extent of absorption as compared to Cardizem tablets.

CONCLUSIONS

Clinical data confirmed that this formulation approach is an effective means to produce a diltiazem sustained release product.

摘要

目的

研发并评估采用Wurster柱法制备的地尔硫䓬缓释微丸的体外/体内性能。

方法

使用Wurster柱,将微粉化盐酸地尔硫䓬、药用包衣材料和乙醇的混悬液喷雾于适当目数的小丸种子上,制备含地尔硫䓬的微丸。采用两步法药物层积工艺将载药量从60%提高至75%。将经烘箱干燥的地尔硫䓬素丸用乙基纤维素/癸二酸二丁酯包衣液包衣,制得地尔硫䓬缓释微丸。采用开放、随机拉丁方、三交叉临床研究评估包衣产品的体内性能。

结果

发现改变该层积工艺起始小丸种子的目数会影响微丸中药物的释放特性。需要进行烘箱干燥步骤以稳定地尔硫䓬素丸。载药层越厚,稳定微丸所需的烘箱干燥时间越长。通过这些方法制备的地尔硫䓬缓释微丸在体外和体内均呈现缓释溶出曲线。与硫氮䓬酮片相比,用0.6%乙基纤维素/癸二酸二丁酯包衣的地尔硫䓬素丸显示出不同的吸收速率(较低的Cmax和较高的Tmax)和相同的吸收程度。

结论

临床数据证实,这种制剂方法是生产地尔硫䓬缓释产品的有效手段。

相似文献

1
Development and in vitro-in vivo evaluation of a multiparticulate sustained release formulation of diltiazem.地尔硫䓬多颗粒缓释制剂的研发及体内外评价
Pharm Res. 1995 Sep;12(9):1338-42. doi: 10.1023/a:1016229808716.
2
Preparation and in vitro evaluation of a novel combined multiparticulate delayed-onset sustained-release formulation of diltiazem hydrochloride.新型盐酸地尔硫䓬组合型多颗粒延迟起效缓释制剂的制备及体外评价
Pharmazie. 2007 Dec;62(12):907-13.
3
Relative bioavailability of Cardizem CD and Tiazac controlled-release diltiazem dosage forms after single and multiple dosing in healthy volunteers.
Am J Ther. 1998 May;5(3):173-9. doi: 10.1097/00045391-199805000-00008.
4
In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride.含盐酸地尔硫䓬的酪蛋白-壳聚糖微球片剂的体外-体内评价
Boll Chim Farm. 2003 Jan-Feb;142(1):14-20.
5
In-vitro and in-vivo characteristics of a modified-release double-pulse formulation for a water soluble drug.一种水溶性药物的缓释双脉冲制剂的体外和体内特性
Int J Clin Pharmacol Ther. 2010 Apr;48(4):250-8. doi: 10.5414/cpp48250.
6
The relative bioavailability of two marketed controlled release diltiazem dosage forms at steady state in healthy volunteers.
Biopharm Drug Dispos. 1996 Jan;17(1):43-53. doi: 10.1002/(SICI)1099-081X(199601)17:1<43::AID-BDD935>3.0.CO;2-F.
7
Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride.含盐酸地尔硫䓬乙基纤维素微球的缓释片的研制与体外评价
J Microencapsul. 2006 Mar;23(2):135-52. doi: 10.1080/02652040500286474.
8
Pharmacokinetics of multiparticulate sustained-release diltiazem preparations in dogs.
J Pharm Sci. 1994 Jan;83(1):38-41. doi: 10.1002/jps.2600830110.
9
Drug-polymer mixed coating: a new approach for controlling drug release rates in pellets.药物-聚合物混合包衣:一种控制微丸药物释放速率的新方法。
Pharm Dev Technol. 2006 Feb;11(1):71-7. doi: 10.1080/10837450500464008.
10
Criteria to assess in vivo performance of sustained release products: application to diltiazem formulations.评估缓释产品体内性能的标准:在硝苯地平制剂中的应用。
J Pharm Sci. 1995 Oct;84(10):1160-3. doi: 10.1002/jps.2600841005.

本文引用的文献

1
Diltiazem. A review of its pharmacological properties and therapeutic efficacy.地尔硫䓬。其药理特性与治疗效果综述。
Drugs. 1985 May;29(5):387-454. doi: 10.2165/00003495-198529050-00001.
2
Performance of diltiazem tablet and multiparticulate osmotic formulations in the dog.
Pharm Res. 1990 Aug;7(8):874-8. doi: 10.1023/a:1015925302374.